Could thymostimulin prevent hepatocellular carcinoma occurrence in patients with liver cirrhosis?

Oncology Reports

Volumn 3, Issue 4, 1996, Pages 655-656

  Palmieri, Giovannella ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

hepatocellular carcinoma; liver cirrhosis; thymostimulin

Indexed keywords

ALPHA FETOPROTEIN; THYMOSTIMULIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG MECHANISM; FEMALE; FOLLOW UP; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; IMMUNOMODULATION; INTRAMUSCULAR DRUG ADMINISTRATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; PRIORITY JOURNAL;

EID: 0029894027     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.3.4.655     Document Type: Article

References (2)

1. Colombo M, De Franchis R, Del Ninno E, Sangiovanni A, De Fazio C, Tommasini M, et al: Hepatoccllular carcinoma in Italian patients with cirrhosis. N Engl J Med 325: 675-680, 1991.
2. Falchetti R, Bergesi G, Eshkol A, Cafiero C, Adorini L and Caprino L: Pharmacological and biological properties of a calf thymus extract (TP-1). Drug Exp Clin Res 3: 39-47, 1977.